U.S. Smart Women's Health Devices Market: $18.2B

Market Outlook

By 2032, the U.S. Smart Women’s Health Devices Market is projected to reach approximately USD 18.24 billion, expanding at a compound annual growth rate (CAGR) of 15.51% during the forecast period 2027–2032. The market stood at USD 7.68 billion in 2026, following historical valuations of USD 4.85 billion in 2023, USD 5.62 billion in 2024, and USD 6.55 billion in 2025. All monetary values within this report are expressed in USD billions.

The U.S. smart women’s health devices industry operates at the convergence of advanced physiological biosensing, personalized digital therapeutics, decentralized clinical trials, artificial intelligence-enabled diagnostic algorithms, ambulatory obstetrical and gynecological monitoring, hospital-at-home care models, and enterprise-grade health data interoperability. Demand is propelled by a structural shift toward proactive, longitudinal female health management across all biological life stages, an institutional migration from episodic in-clinic interventions to continuous decentralized monitoring, and increased capital investment in purpose-engineered technologies for female biology. In 2024, female healthcare consumers made or influenced approximately 80% of healthcare purchasing decisions in the United States, while the female population of roughly 168 million individuals accounted for disproportionate annual per-capita medical expenditures compared to males, driven by pregnancy, childbirth, reproductive disorders, pelvic health conditions, and post-menopausal chronic disease management. Total direct and indirect U.S. healthcare expenditures for gynecological, reproductive, maternal, and breast health conditions surpassed USD 158.00 billion in 2024, with technology-enabled medical devices, connected biosensors, and digital therapeutics capturing more than USD 28.50 billion of active clinical and consumer-directed procurement.

The clinical profile of female patients is increasingly viewed through the lens of sex-specific physiological variation, establishing durable, long-term device utilization patterns across reproductive, maternal, and post-reproductive lifespans. Approximately 12% of women of reproductive age in the United States, or roughly 7.3 million individuals, experience impaired fecundity or clinical infertility, while polycystic ovary syndrome (PCOS) and endometriosis affect an estimated 10% to 15% of biological females, driving sustained demand for precision ovulation biosensors, continuous hormone tracking hardware, and non-invasive transdermal diagnostic monitors. Concurrently, maternal mortality and morbidity rates in the United States remain the highest among industrialized economies, recording approximately 22.3 maternal deaths per 100,000 live births in 2023, accompanied by severe maternal morbidity events affecting more than 60,000 women annually. Managing these acute and chronic conditions requires specialized, connected medical devices that bridge the critical gap between inpatient labor-and-delivery units, maternal-fetal medicine clinics, and remote home monitoring, including wireless continuous fetal-maternal cardiotocography sensors, cloud-integrated wearable blood pressure cuffs for preeclampsia tracking, smart hospital-grade wearable breast pumps, connected pelvic floor rehabilitation trainers, and point-of-care digital breast imaging modalities.

The modernization of commercial payer reimbursement policies and corporate employer-sponsored health benefits has fundamentally altered clinical procurement behavior. Large commercial health plans, including UnitedHealthcare, Elevance Health, Aetna, and Cigna, alongside self-insured employer health coalitions representing over 65% of commercially insured American workers, have established dedicated benefit riders covering connected maternity care, remote patient monitoring (RPM) for high-risk pregnancies, pelvic floor dysfunction digital therapy, and lactation technology. Centers for Medicare & Medicaid Services (CMS) remote physiologic monitoring codes (CPT 99453, 99454, 99457, and 99458) have institutionalized clinical reimbursement pathways for smart obstetrical and gynecological hardware, enabling obstetricians, urogynecologists, and primary care networks to generate recurring monthly clinical revenue by prescribing cellular-connected biosensing devices. This structural reimbursement evolution has shifted device monetization from purely out-of-pocket, consumer-directed purchasing toward hybrid, dual-path distribution models combining direct-to-consumer digital commerce with formal clinician-prescribed, insurance-reimbursed clinical device pathways.

Concurrently, the historical medical practice of treating female patients using adapted, male-normed clinical hardware and empirical diagnostics is being dismantled. Biological variations in female endocrine cycles, core body temperature regulation, subcutaneous breast tissue density, pelvic anatomy, and cardiovascular hemodynamic responses have driven demand for female-specific medical hardware. Medical device engineers are developing micro-machined biosensors, multi-wavelength photoplethysmography (PPG) arrays, sub-millimeter transvaginal pressure transducer arrays, low-dose digital photon-counting mammography detectors, and point-of-care cervical colposcopy scanners with automated edge-AI lesion classification. These female-specific platforms eliminate diagnostic ambiguity, optimize clinical intervention windows, improve patient therapeutic compliance, and reduce avoidable emergency room visits and neonatal intensive care unit (NICU) admissions.

The historical market expanded rapidly from 2023 through 2025 as health systems accelerated the adoption of decentralized maternal health protocols, cleared post-pandemic backlogs of elective urogynecological and pelvic floor reconstructive procedures, and deployed connected home-use lactation platforms to accommodate hybrid workplace demands. From 2027 onward, market expansion will be catalyzed by therapeutic and diagnostic platforms, including automated non-invasive hormone quantification wearables, AI-driven wireless fetal monitoring patches, non-invasive transdermal endometriosis screening devices, connected biofeedback pelvic trainers with real-time electromyography (EMG), automated ultrasound breast screening attachments for home-use telehealth, and prescription-grade digital therapeutics addressing post-menopausal vasomotor symptoms and osteoporosis.

Introduction

The smart women’s health devices sector represents one of the fastest-evolving segments within the American medical technology landscape, marked by a clinical transition from episodic, reactive care toward continuous, precision-guided biological intervention. A female patient today navigates a connected continuum of care spanning multiple life phases. A patient may initially monitor menstrual and ovulatory biomarker fluctuations using a continuous transdermal temperature sensor or saliva-based biosensor, transition into clinical fertility treatment utilizing connected semen-ovum interaction monitors and microfluidic hormone tracking devices, navigate high-risk pregnancy via FDA-cleared wireless fetal heart rate and maternal uterine contraction monitors, recover postpartum through connected pneumatic breast pumps and app-integrated pelvic floor biofeedback trainers, and ultimately manage perimenopausal and postmenopausal transitions using transdermal vasomotor monitoring wearables and connected bone density screening platforms.

This connected continuum establishes a commercially robust ecosystem characterized by recurring hardware replenishment, consumable fluidics, sensor replacements, software-as-a-service (SaaS) subscriptions, and institutional enterprise data licensing. Therapeutic and diagnostic smart women’s health devices form the foundation of clinical revenue, while remote pregnancy monitoring platforms and connected pelvic floor rehabilitation systems represent the fastest-scaling capital and prescription categories across health systems, independent obstetrics and gynecology practices, and corporate reproductive health networks. The economic fundamentals of modern outpatient gynecological and obstetrical clinics dictate that connected health devices must demonstrate clinical diagnostic accuracy, frictionless electronic health record (EHR) integration, intuitive patient usability, and immediate procedural or remote monitoring billability. Unlike traditional consumer wellness gadgets that lack clinical validation, smart women’s health devices increasingly secure 510(k) clearances or De Novo classifications from the U.S. Food and Drug Administration (FDA), allowing clinicians to integrate device-derived data directly into clinical decision-support workflows.

The expansion of remote physiologic monitoring and remote therapeutic monitoring (RTM) reimbursement codes has expanded clinical utilization thresholds for connected female health platforms. When an obstetrician prescribes a cellular-connected continuous fetal-maternal telemetry patch to an expectant mother diagnosed with gestational hypertension, intrauterine growth restriction, or chronic preeclampsia, the health system can bill for device setup, 30-day device supply, and cumulative physician review time. Insured female patients experience improved clinical outcomes, as continuous remote tracking enables earlier detection of hypertensive spikes, fetal tachycardia, and uterine hyperstimulation, thereby preventing emergency cesarean sections and catastrophic maternal-fetal outcomes. This clinical and economic validation insulates the smart women’s health device sector from discretionary consumer spending contractions, providing hospital supply chain executives and corporate practice directors with fiscal justification to invest in enterprise software licenses and device fleets.

Clinical operations within obstetrical, gynecological, and maternal-fetal medicine clinics differ from general internal medicine environments. Women’s health clinics manage high patient volumes, experience acute nursing and ultrasound sonographer shortages, and navigate strict liability concerns surrounding maternal and neonatal safety. Devices engineered for this environment must streamline clinical documentation, automate artifact rejection in biosignal processing, and offer intuitive patient-facing interfaces that minimize patient user error. A modern wireless fetal monitor, for example, integrates multi-crystal ultrasound transducers and wide-beam maternal ECG leads into a single lightweight adhesive patch, automatically transmitting digitized cardiotocography data to centralized labor-and-delivery telemetry consoles and maternal-fetal medicine EHR modules, reducing clinician setup time by more than 50% compared to traditional wired abdominal belt systems.

The market environment is further characterized by the rapid expansion of direct-to-consumer digital health platforms and hybrid virtual-first obstetrical-gynecological clinics. Telehealth entities such as Maven Clinic, Tia Health, Kindbody, and Ro have integrated smart medical hardware directly into their clinical care pathways. These virtual providers ship cellular-connected diagnostic kits, smart basal body temperature sensors, and wireless blood pressure monitors directly to patients’ homes, pairing hardware telemetry with synchronous telemedicine consultations. This direct-to-consumer clinical fulfillment model expands device distribution beyond conventional hospital supply chains and specialty pharmacies, accelerating device adoption across younger, digitally fluent demographics.

From 2027 through 2032, device vendors will compete across integrated, cloud-native female healthcare ecosystems. Leading manufacturers are embedding edge machine learning into physiological biosensors, linking ambulatory device streams with major EHR platforms via FHIR-based APIs, and coupling physical hardware with predictive algorithms that forecast ovulatory windows, preterm labor onset, pelvic floor prolapse progression, and perimenopausal bone mineral density decline. The dominant market leaders will be those who deliver clinical reliability, rigorous clinical trial validation, seamless interoperability, and end-to-end data privacy protections tailored to female health metrics.

Key Market Drivers: What’s Fueling the U.S. Smart Women’s Health Devices Market Boom?

The first primary growth driver is the expansion of clinical remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement coverage by commercial payers and CMS, paired with corporate employer investments in female healthcare benefits. Commercial insurers recognize that preterm birth and maternal morbidity represent substantial drivers of annual medical claims, with average NICU hospitalization costs exceeding USD 50,000 to USD 100,000 per infant. By establishing formal coverage pathways for connected fetal-maternal monitors, smart preeclampsia monitoring cuffs, and connected gestational diabetes biosensors, payers achieve immediate medical cost savings through early clinical intervention. Furthermore, Fortune 500 employers are utilizing specialized female health benefit packages—encompassing smart breast pumps, connected fertility monitors, and virtual pelvic therapy devices—as a talent recruitment and retention mechanism for professional female employees, driving institutional purchasing of smart devices.

A second driver is the clinical mandate to address the maternal health crisis in the United States through decentralized, continuous hemodynamic and fetal tracking. The persistent disparity in maternal health outcomes, particularly among minority, rural, and economically disadvantaged populations, has prompted federal and state health agencies to enact maternal health modernization programs, such as the White House Blueprint for Addressing the Maternal Health Crisis. Traditional obstetrical care relies on sporadic, monthly in-person clinic visits that often fail to detect sudden-onset gestational hypertension, preeclampsia, or fetal distress occurring between appointments. Connected, hospital-grade maternal biosensors allow maternal-fetal medicine specialists to continuously track uterine tone, maternal heart rate, continuous blood pressure, and fetal heart rate patterns while patients remain at home, enabling proactive clinical intervention before complications escalate into medical emergencies.

A third driver is the growing clinical specialization and mainstream medical validation of female pelvic floor medicine and urogynecological digital therapeutics. Pelvic floor disorders, including stress urinary incontinence, urge incontinence, pelvic organ prolapse, and levator ani dysfunction, affect approximately one in three American women over their lifetimes, yet historically suffered from clinical neglect and patient stigma. The introduction of FDA-cleared, app-connected pelvic floor biofeedback trainers equipped with high-resolution micro-electromyography (EMG) sensors and pneumatic pressure transducers has shifted clinical treatment protocols. Urogynecologists, physical therapists, and OB/GYN clinicians routinely prescribe these smart biofeedback devices as first-line conservative therapy prior to considering surgical intervention with mesh or slings, creating a high-volume clinical distribution pipeline supported by CPT reimbursement codes for pelvic muscle neuromuscular re-education.

A fourth driver is the technological convergence of miniaturized biosensing, transdermal microfluidics, and edge artificial intelligence that enables continuous, non-invasive biomarker tracking. Historically, women tracking reproductive cycles, ovulation windows, or endocrine disorders relied on manual urine strip tests or episodic clinical blood draws that provided static, retrospective snapshots. Modern smart women’s health devices incorporate optical photoplethysmography, galvanic skin response, continuous basal temperature arrays measuring to within 0.01 degrees Celsius, and transdermal biosensors capable of analyzing interstitial fluid or saliva. Embedded AI algorithms normalize raw physiological signals against individual baseline variations, providing real-time predictive insights regarding the luteinizing hormone surge, fertile window opening, and early pregnancy implantation, thereby improving diagnostic accuracy and clinical utility for both patients and reproductive endocrinologists.

A fifth driver is the transformation of lactation and neonatal nutrition technology through the rise of smart, wearable, hands-free breast pumps and connected lactation management platforms. Modern professional women face challenges balancing sustained breastfeeding with demanding career schedules, driving demand for whisper-quiet, motor-integrated wearable pumps that fit discreetly inside standard nursing bras. Advanced connected breast pumps incorporate micro-diaphragm pumping systems, automated flow-rate sensors, dynamic compression algorithms that mimic infant suckling patterns, and cloud-synchronized mobile applications that track session volumes, pumping duration, and nutritional output. The commercialization of these smart pumps has been accelerated by provisions within the Affordable Care Act that mandate commercial insurance coverage of lactation equipment, alongside the federal PUMP for Nursing Mothers Act, which enforces workplace lactation accommodations, stimulating consistent replacement cycles and recurring consumable revenue streams.

A sixth driver is the demographic transition of the Millennial and Generation Z cohorts into peak reproductive, maternal, and perimenopausal ages, driving demand for digital-first, consumer-centric clinical hardware. These cohorts expect healthcare interactions to match the digital convenience, mobile-first connectivity, and transparent data access experienced across modern consumer technology ecosystems. When experiencing reproductive challenges, pregnancy, postpartum recovery, or early perimenopausal symptoms, digitally native female consumers bypass legacy manual products in favor of connected medical devices featuring Bluetooth Low Energy (BLE) connectivity, automated cloud synchronization, actionable digital dashboards, and direct telemedicine integration. This consumer demographic shift provides medtech manufacturers with high organic adoption rates and lowers customer acquisition costs across both retail and prescription channels.

Finally, the expanding clinical recognition and private equity financing directed toward the femtech and dedicated women’s health device sector have generated substantial research and development capital. Over the past five years, institutional venture capital, private equity platforms, and dedicated healthcare funds have deployed billions of dollars into female-focused device engineering, multi-center clinical trials, and regulatory clearance pathways. This capital infusion has accelerated product development lifecycles, enabling startups and established medtech conglomerates to conduct rigorous, peer-reviewed clinical studies that validate the safety, efficacy, and economic utility of smart women’s health devices, ultimately driving institutional adoption across hospital purchasing committees and group purchasing organizations (GPOs).

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation across the U.S. smart women’s health devices market is transforming conventional, episodic medical apparatus into intelligent, continuous, and highly integrated therapeutic and diagnostic platforms. Competitive differentiation has evolved beyond basic industrial design toward integrated platforms combining proprietary sensor architectures, edge AI processing, clinical-grade biocompatible materials, closed-loop biofeedback mechanisms, and bidirectional EHR data integration.

In maternal and fetal monitoring, hardware engineering has transitioned away from bulky, wired cardiotocography machines toward wireless, patch-based telemetry platforms. Leading medtech developers have engineered flexible, skin-adherent acoustic and electrophysiological sensor patches that capture high-fidelity maternal ECG, fetal ECG, and uterine electromyography signals directly through the maternal abdominal wall. Advanced digital signal processing algorithms execute real-time maternal-fetal separation, eliminating the maternal pulse contamination that frequently causes false alarms in conventional Doppler ultrasound monitors. These wearable patches are designed to maintain skin adhesion for up to seven continuous days, incorporating onboard microcontrollers that run continuous arrhythmia and uterine tachysystole detection algorithms at the edge, transmitting encrypted clinical-grade telemetry via cellular networks to labor-and-delivery nursing stations and obstetrician mobile dashboards without requiring a paired smartphone or local Wi-Fi infrastructure.

In pelvic health and urogynecological rehabilitation, device manufacturers have introduced smart intra-vaginal and external biofeedback trainers that utilize multi-axis pressure transducer arrays coupled with dynamic electromyography. Unlike historical Kegel training devices that merely measured aggregate vaginal squeeze pressure, modern smart pelvic trainers evaluate intra-pelvic vector forces, differentiating between correct pelvic floor contractions and counter-productive intra-abdominal bearing-down maneuvers. Proprietary firmware translates real-time muscular contractions into visual biofeedback gamification on mobile interfaces, guiding patients through calibrated neuromuscular strength, endurance, and rapid-twitch motor unit exercises. Leading devices incorporate closed-loop neuromuscular electrical stimulation (NMES) and transcutaneous tibial nerve stimulation (TTNS) capabilities, automatically adjusting electrical pulse frequencies and amplitudes based on real-time muscle fatigue indices to rehabilitate refractory stress and urge incontinence.

Connected fertility and endocrine tracking devices have undergone an engineering transformation characterized by non-invasive biomarker sensing and transdermal micro-sensing. Leading innovators have developed clinical-grade smart rings, wrist-worn wearables, and continuous intradermal sensor patches that monitor multi-system biometrics throughout the 24-hour circadian and infradian cycles. These biosensors simultaneously track continuous wrist skin temperature, heart rate variability (HRV), photoplethysmography-derived pulse transit time, skin perfusion, and galvanic skin conductance. Embedded artificial intelligence engines process these multi-parameter biometric streams to identify the subtle, multi-organ physiological shifts that precede the luteinizing hormone (LH) surge by up to four days, providing prospective, rather than retrospective, ovulation detection with clinical accuracy matching transvaginal ultrasound folliculometry. Concurrently, microfluidic optical analyzers for home saliva and urine testing utilize microscopic lens attachments and smartphone camera optics to quantify estrone-3-glucuronide (E1G), pregnanediol-3-glucuronide (PdG), follicle-stimulating hormone (FSH), and luteinizing hormone concentrations within minutes, standardizing biomarker quantification without laboratory visits.

In lactation technology, the integration of micro-piezoelectric air pumps, smart flow sensors, and adaptive suction algorithms has redefined the operational mechanics of breast pumps. Legacy breast pumps relied on loud, oscillating mechanical diaphragm motors and rigid plastic collection flanges that required external power cords and manual handling. Modern smart wearable breast pumps integrate miniature piezoelectric motors directly into lightweight, anatomical collection cups that contour naturally to breast morphology. Embedded infrared optical flow sensors quantify real-time milk let-down velocity and volume accumulation at sub-milliliter resolutions, transmitting real-time extraction curves to onboard microprocessors that automatically adjust suction cycle rhythms, vacuum pressure levels, and stimulation-to-expression transitions based on the user’s milk ejection reflex. Furthermore, cloud-integrated companion applications aggregate longitudinal pumping output data, cross-referencing nutritional volumes with maternal sleep quality, hydration, and postpartum medication regimens to optimize lactation guidance.

Point-of-care breast and cervical diagnostic screening technologies are shifting advanced cancer detection from dedicated hospital imaging suites into community outpatient clinics and mobile screening environments. Medtech pioneers have introduced handheld, battery-powered digital colposcopes equipped with multi-spectral light-emitting diodes (LEDs) and high-resolution optical sensors that capture microscopic cervical imagery. Embedded deep learning algorithms trained on hundreds of thousands of histologically confirmed cervical lesions automatically identify acetowhite changes, atypical vascular patterns, and high-grade cervical intraepithelial neoplasia (CIN 2/3), providing immediate risk-stratification scores at the point of care. In breast health, innovations include wearable dynamic optical imaging pads that detect angiogenic metabolic heat signatures and vascular density variations associated with early-stage malignant tumors, alongside handheld, automated breast ultrasound (ABUS) probes that integrate with tablet interfaces, enabling non-radiologist clinicians to capture standardized, multi-planar breast tissue volumes for remote cloud-based interpretation by specialty breast radiologists.

Digital therapeutics and connected neuromodulation hardware are advancing into the management of perimenopause, menopause, and dysmenorrhea. Transcutaneous electrical nerve stimulation (TENS) and targeted pulsed electromagnetic field (PEMF) devices have been miniaturized into discrete, skin-adherent wearable pods engineered for severe menstrual cramping and chronic pelvic pain associated with endometriosis. These connected pods utilize active frequency-hopping algorithms that prevent peripheral nerve adaptation, controlled via smartphone applications that allow patients to fine-tune therapeutic intensity. For perimenopausal women, connected wrist-worn thermal neuromodulation devices detect physiological precursors of hot flashes—including rapid cutaneous vasodilatation and autonomic nervous system tone shifts—and deliver localized thermal cooling pulses to the median nerve, disrupting the central thermoregulatory panic response in the hypothalamus and reducing subjective hot flash severity and nocturnal sleep disturbances.

Segmentation Insights

The U.S. Smart Women’s Health Devices Market is segmented on the basis of Product Type, Application, Modality and Form Factor, Technology and Connectivity, End User, and Geography.

By Product Type

The U.S. Smart Women’s Health Devices Market by product type is segmented into Connected Maternal and Fetal Monitors, Smart Wearable Breast Pumps, Smart Pelvic Floor Rehabilitation Devices, Connected Fertility and Ovulation Trackers, and Point-of-Care Diagnostic and Screening Devices.

Connected Maternal and Fetal Monitors
Connected maternal and fetal monitors represent the largest product category, accounting for USD 2.52 billion in 2026, up from USD 1.55 billion in 2023, USD 1.81 billion in 2024, and USD 2.13 billion in 2025. The category is projected to reach USD 6.13 billion by 2032, advancing at a 15.98% CAGR from 2027 to 2032. This segment encompasses wireless ambulatory cardiotocography (CTG) systems, patch-based maternal-fetal electrocardiography monitors, cellular-connected remote blood pressure monitoring cuffs calibrated for gestational hypertension, and continuous wearable uterine activity sensors.

The revenue scale of this segment is driven by the clinical urgency to reverse rising U.S. maternal mortality and morbidity rates, coupled with the rapid institutional expansion of virtual obstetrical clinics and hospital-at-home high-risk pregnancy pathways. Leading healthcare networks are replacing traditional, tethered bedside Doppler ultrasound monitors with cable-free, multi-sensor adhesive patches that permit continuous patient ambulation during labor while maintaining diagnostic signal fidelity. In outpatient environments, remote monitoring platforms allow maternal-fetal medicine specialists to supervise pregnancies complicated by preeclampsia, gestational diabetes, and advanced maternal age, tracking real-time hemodynamic and fetal cardiac data from the home. Automated alert engines embedded in clinical dashboards triage physiological variations, ensuring timely intervention and reducing unnecessary antepartum emergency room admissions.

Smart Wearable Breast Pumps
Smart wearable breast pumps accounted for USD 2.04 billion in 2026, following historical revenues of USD 1.31 billion in 2023, USD 1.51 billion in 2024, and USD 1.75 billion in 2025. This segment is projected to achieve USD 4.67 billion by 2032, expanding at a 14.80% CAGR from 2027 to 2032. Equipment within this domain includes tubeless, in-bra wearable electronic breast pumps, hospital-grade smart dual-electric pumps, Bluetooth-integrated micro-diaphragm pumping systems, and connected milk storage ecosystems with automated volume tracking.

Commercial demand is sustained by the high labor force participation rate of American mothers, structural workplace lactation accommodations established under the PUMP for Nursing Mothers Act, and widespread commercial health insurance coverage for breast pumps under the Affordable Care Act. Modern nursing mothers prioritize hands-free, silent, and discreet devices that can be worn under business or casual attire without external tubes, bottles, or cords. Manufacturers are gaining market share by integrating micro-piezoelectric pumping engines, anatomical silicone flanges, and automated milk flow sensors that monitor expression rates in real time. Connected smartphone applications empower users to adjust suction patterns across multi-phase expression cycles, log milk output volumes, track maternal hydration, and synchronize pumping data directly with pediatric growth-tracking applications.

Smart Pelvic Floor Rehabilitation Devices
Smart pelvic floor rehabilitation devices generated USD 1.27 billion in 2026, rising from USD 0.78 billion in 2023, USD 0.91 billion in 2024, and USD 1.07 billion in 2025. The segment is on track to reach USD 3.10 billion by 2032, demonstrating a 16.03% CAGR from 2027 to 2032. This category comprises app-connected intra-vaginal biofeedback trainers, high-resolution electromyography (EMG) probe sensors, surface-sensor pelvic floor tracking systems, closed-loop neuromuscular electrical stimulation (NMES) devices, and transcutaneous tibial nerve stimulation (TTNS) hardware for overactive bladder.

The growth trajectory of this segment stems from the widespread prevalence of pelvic floor dysfunction, including urinary incontinence, pelvic organ prolapse, and postpartum pelvic floor weakness, which affects more than 28 million women across the United States. Historically, conservative pelvic therapy was constrained by patient non-adherence and difficulty isolating the levator ani muscles during unassisted home exercises. Smart pelvic trainers overcome these limitations by utilizing multi-axis pressure sensors and dynamic EMG biofeedback, providing real-time visual gamification on mobile interfaces that guides correct muscle contraction and relaxation. Urogynecologists, obstetricians, and physical therapists are prescribing these devices as first-line conservative therapy, supported by commercial and Medicare reimbursement codes for pelvic muscle neuromuscular re-education and remote therapeutic monitoring.

Connected Fertility and Ovulation Trackers
Connected fertility and ovulation trackers accounted for USD 1.13 billion in 2026, expanding from historical figures of USD 0.73 billion in 2023, USD 0.84 billion in 2024, and USD 0.97 billion in 2025. By 2032, the category is projected to reach USD 2.59 billion, reflecting a 14.83% CAGR from 2027 to 2032. Products include smart continuous basal body temperature (BBT) sensors, multi-sensor fertility smart rings and wristbands, continuous transdermal hormone monitoring patches, connected optical saliva microscopes, and digital urine biomarker analyzers with microfluidic cartridges.

Market expansion is driven by the demographic delay in family planning, rising maternal age at first pregnancy, and growing consumer demand for non-invasive, hormone-free family planning alternatives. Connected fertility devices replace traditional manual urine test strips and single-point morning temperature measurements with continuous biometric monitoring throughout the sleep cycle. By capturing micro-fluctuations in skin temperature down to 0.01 degrees Celsius, resting heart rate, and heart rate variability, predictive algorithms identify the onset of the fertile window up to four days prior to ovulation. Furthermore, multi-hormone digital analyzers enable women with polycystic ovary syndrome (PCOS) and irregular menstrual cycles to track luteinizing hormone, estrogen, and progesterone metabolites quantitatively at home, providing reproductive endocrinologists with longitudinal endocrine profiles that optimize natural conception and assisted reproductive technology (ART) cycles.

Point-of-Care Diagnostic and Screening Devices
Point-of-care diagnostic and screening devices generated USD 0.72 billion in 2026, having grown from USD 0.48 billion in 2023, USD 0.55 billion in 2024, and USD 0.63 billion in 2025. This category is anticipated to achieve USD 1.75 billion by 2032, expanding at a 15.96% CAGR from 2027 to 2032. The segment includes handheld digital colposcopes with integrated edge-AI diagnostic aids, automated point-of-care breast ultrasound screening scanners, portable transvaginal ultrasound probes interfacing with smart tablets, and connected non-invasive bone mineral density screening devices for osteoporosis.

The steady expansion of this category reflects the institutional decentralization of specialized gynecological, oncological, and breast screening services from tertiary cancer centers into community health centers, primary care practices, and retail health clinics. Handheld digital colposcopes equipped with optical zoom and real-time machine learning algorithms assist general practitioners in identifying high-grade cervical intraepithelial neoplasias during routine speculum examinations, mitigating diagnostic disparities across underserved clinical environments. In breast imaging, automated handheld ultrasound devices and tactile imaging platforms provide safe, radiation-free supplemental screening for women with dense breast tissue—a demographic comprising more than 40% of American women whose mammograms often yield false-negative results.

By Application

The U.S. Smart Women’s Health Devices Market by application is segmented into Pregnancy and Postpartum Care, Fertility and Reproductive Health, Pelvic and Urological Health, Oncology and Preventive Screening, and Menopause and Endocrine Management.

Pregnancy and Postpartum Care
Pregnancy and postpartum care represents the premier application category, accounting for USD 3.23 billion in 2026, following historical figures of USD 2.01 billion in 2023, USD 2.34 billion in 2024, and USD 2.74 billion in 2025. This segment is projected to reach USD 7.74 billion by 2032, expanding at a 15.68% CAGR from 2027 to 2032. Clinical indications encompass antepartum high-risk maternal-fetal surveillance, intrapartum labor progression tracking, postpartum hemorrhage early detection, remote preeclampsia monitoring, and postpartum lactation support.

The dominance of this application is anchored in the clinical continuum of obstetric medicine, which requires intensive medical surveillance over a defined, critical time window. Obstetrical health systems and commercial payers prioritize investments in maternal health monitoring devices because timely management of gestational hypertension, preeclampsia, and preterm labor directly prevents catastrophic maternal injuries and long-term neonatal intensive care stays. Postpartum care has gained attention as maternal health guidelines expand follow-up care beyond the historical six-week post-delivery visit into an ongoing, 12-week “fourth trimester.” Connected blood pressure cuffs, mental health biometric trackers, and hands-free smart wearable breast pumps provide support during this vulnerable transition, driving clinical hardware utilization and recurring software subscriptions.

Fertility and Reproductive Health
Fertility and reproductive health accounted for USD 1.80 billion in 2026, up from historical levels of USD 1.14 billion in 2023, USD 1.32 billion in 2024, and USD 1.54 billion in 2025. The segment is on track to reach USD 4.22 billion by 2032, growing at a 15.25% CAGR from 2027 to 2032. Applications include natural conception optimization, assisted reproductive technology (ART) cycle preparation, polycystic ovary syndrome (PCOS) symptom tracking, luteal phase defect identification, and digital contraceptive biomarker monitoring.

This application is propelled by the rising prevalence of secondary and primary infertility, shifting demographic trends toward delayed childbearing, and consumer preference for objective biological data over manual calendar calculations. Modern fertility patients utilize connected biosensors and microfluidic hormone analyzers to map their reproductive cycles with laboratory precision. Reproductive endocrinologists and fertility clinics integrate patient-generated device data into electronic medical records to schedule intrauterine inseminations (IUI), optimize in vitro fertilization (IVF) ovarian stimulation protocols, and diagnose ovulatory dysfunction. The integration of clinical fertility hardware within employer-sponsored family-building benefits has expanded patient access, allowing prospective parents to expense connected fertility kits through healthcare flexible spending accounts (FSA) and health savings accounts (HSA).

Pelvic and Urological Health
Pelvic and urological health generated USD 1.29 billion in 2026, expanding from historical revenues of USD 0.81 billion in 2023, USD 0.94 billion in 2024, and USD 1.10 billion in 2025. The category is projected to reach USD 3.12 billion by 2032, advancing at a 15.86% CAGR from 2027 to 2032. Indications encompass stress urinary incontinence, overactive bladder and urge incontinence, pelvic organ prolapse stage I and II, levator ani myalgia, postpartum pelvic diastasis, and pelvic floor hypertonicity.

Demand across this clinical domain is sustained by the aging female population and growing rejection of invasive surgical mesh procedures in favor of conservative, technology-enabled neuromuscular rehabilitation. Smart pelvic floor devices provide localized biofeedback, electromyographic measurement, and closed-loop electrical stimulation, enabling patients to perform pelvic floor rehabilitation exercises correctly in the privacy of their homes. Clinical studies demonstrating that guided biofeedback training yields continence rates comparable to mid-urethral sling surgery have driven clinical endorsement from the American College of Obstetricians and Gynecologists (ACOG) and the American Urogynecologic Society (AUGS). Furthermore, digital connectivity enables urogynecologists and pelvic physical therapists to remotely monitor patient adherence, contraction duration, and resting baseline muscle tone, optimizing physical therapy adjustments via telehealth consultations.

Oncology and Preventive Screening
Oncology and preventive screening accounted for USD 0.82 billion in 2026, having grown from USD 0.53 billion in 2023, USD 0.61 billion in 2024, and USD 0.70 billion in 2025. By 2032, the category is projected to reach USD 1.94 billion, reflecting a 15.43% CAGR from 2027 to 2032. Clinical procedures include cervical cancer screening and colposcopy triage, dense breast tissue supplemental screening, non-invasive breast tumor vascular imaging, and early-stage ovarian cancer biomarker detection.

The growth of this application is accelerated by updated breast and cervical cancer screening guidelines and federal mandates enforcing patient notification regarding breast tissue density. Because dense breast tissue obscures cancerous lesions on traditional two-dimensional mammograms and doubles lifetime breast cancer risk, healthcare providers are deploying supplemental screening modalities, including connected automated handheld breast ultrasound and optical vascular imaging pads. In cervical oncology, the global effort to eliminate cervical cancer has driven primary care and community gynecological clinics to adopt smart, digital colposcopes with edge-AI lesion classification algorithms. These devices provide visual diagnostic verification of suspicious lesions, guiding targeted cervical biopsies and reducing unnecessary diagnostic excisions in reproductive-aged women.

Menopause and Endocrine Management
Menopause and endocrine management generated USD 0.54 billion in 2026, up from historical levels of USD 0.36 billion in 2023, USD 0.41 billion in 2024, and USD 0.47 billion in 2025. The segment is on track to achieve USD 1.22 billion by 2032, demonstrating a 14.55% CAGR from 2027 to 2032. Indications include perimenopausal vasomotor symptom (hot flash) regulation, nocturnal thermal disturbance tracking, postmenopausal osteopenia and osteoporosis bone density monitoring, and chronic metabolic and cardiovascular tracking in post-reproductive women.

This application represents an emerging growth frontier within the female healthcare market, driven by demographic expansion as approximately 1.3 million American women enter menopause annually. The commercial market has historically underserved the menopausal transition, treating hot flashes, sleep fragmentation, and mood disturbances with empirical hormone replacement therapy or lifestyle adjustments. Modern medtech vendors have commercialized connected wearable devices that deliver targeted thermal neuromodulation to abort hot flashes in real time, alongside connected biosensing wearables that map sleep-architecture disruption and autonomic nervous system stress. Concurrently, portable, radiation-free ultrasound and radiofrequency bone densitometers are expanding access to osteoporosis screening in outpatient OB/GYN clinics, identifying early bone mineral loss years before symptomatic osteoporotic fractures occur.

By Modality and Form Factor

The U.S. Smart Women’s Health Devices Market by modality and form factor is segmented into Wearable and Body-Worn Sensors, Handheld and Portable Diagnostic Devices, Intracavity and Insertable Devices, and Tabletop and Stationary Home Consoles.

Wearable and Body-Worn Sensors
Wearable and body-worn sensors represent the largest form factor category, accounting for USD 3.63 billion in 2026, following historical figures of USD 2.23 billion in 2023, USD 2.61 billion in 2024, and USD 3.07 billion in 2025. The category is projected to reach USD 8.87 billion by 2032, expanding at a 16.05% CAGR from 2027 to 2032. Products include smart rings, continuous wrist-worn multi-sensor bands, in-bra wearable breast pumps, skin-adherent maternal-fetal ECG patches, and wearable thermal neuromodulation wristbands.

The dominance of wearable form factors is rooted in patient preference for non-obtrusive, continuous physiological monitoring that integrates into daily routines without requiring conscious behavioral intervention. Advanced semiconductor miniaturization, flexible printed electronics, and ultra-low-power microcontrollers allow device manufacturers to engineer body-worn devices that capture clinical-grade biometric data continuously for multiple days on a single battery charge. In maternal care, flexible abdominal patches eliminate restrictive wired belts, allowing pregnant women to work, sleep, and exercise while their clinician monitors cardiotocography telemetry. In lactation, wearable in-bra pumps allow nursing mothers to express milk discreetly in workplace environments, removing the social, physical, and operational barriers historically associated with traditional breast pumping.

Handheld and Portable Diagnostic Devices
Handheld and portable diagnostic devices accounted for USD 1.84 billion in 2026, up from historical levels of USD 1.18 billion in 2023, USD 1.36 billion in 2024, and USD 1.58 billion in 2025. The segment is on track to reach USD 4.29 billion by 2032, exhibiting a 15.15% CAGR from 2027 to 2032. Products encompass battery-powered digital colposcopes, pocket-sized ultrasound scanners, handheld hormone readers, digital pelvic examination wands, and point-of-care transcutaneous bone densitometers.

The expansion of handheld diagnostic devices is driven by the clinical decentralization of female medical care and the proliferation of outpatient ambulatory clinics, urgent care centers, and home-based visiting nurse services. Handheld devices eliminate the need for heavy, stationary capital equipment, enabling clinicians to perform high-resolution optical and ultrasonic examinations at the point of care. These devices incorporate high-capacity lithium-ion batteries, durable drop-resistant enclosures, and direct wireless casting capabilities to commercial tablets or smartphones. Point-of-care ultrasound probes utilizing silicon-based capacitive micromachined ultrasonic transducers (CMUTs) allow obstetricians and gynecologists to perform pelvic anatomy assessments, confirm intrauterine pregnancies, and evaluate amniotic fluid indices directly at the patient’s bedside.

Intracavity and Insertable Devices
Intracavity and insertable devices generated USD 1.38 billion in 2026, having grown from USD 0.90 billion in 2023, USD 1.03 billion in 2024, and USD 1.19 billion in 2025. By 2032, the category is projected to achieve USD 3.20 billion, advancing at a 15.04% CAGR from 2027 to 2032. This domain includes smart intra-vaginal pelvic floor biofeedback trainers, continuous intravaginal core temperature monitoring sensors, connected clinical pessaries with embedded pressure transducers, and electronic vaginal dilator systems with integrated biofeedback.

The commercial growth of insertable devices is underpinned by their clinical efficacy in isolating deep pelvic floor musculature and capturing true core physiological biometrics. Intracavity pelvic trainers manufactured from medical-grade, biocompatible liquid silicone rubber house sub-millimeter micro-machined pressure sensors and gold-plated electromyographic electrodes. These sensors interface directly with the levator ani and pubococcygeus muscles, providing biomechanical measurement accuracy that surface-patch electrodes cannot replicate due to soft-tissue signal attenuation. Furthermore, insertable continuous core temperature sensors worn intravaginally overnight capture true circadian nadir temperatures, eliminating the environmental artifacts that distort skin-temperature fertility tracking.

Tabletop and Stationary Home Consoles
Tabletop and stationary home consoles accounted for USD 0.83 billion in 2026, following historical revenues of USD 0.54 billion in 2023, USD 0.62 billion in 2024, and USD 0.71 billion in 2025. The segment is projected to reach USD 1.88 billion by 2032, growing at a 14.61% CAGR from 2027 to 2032. Products include countertop microfluidic hormone analyzers, hospital-grade home breast pump multi-user stations, tabletop pelvic health stimulation hubs, and stationary maternal health telemonitoring terminals.

While portable and wearable form factors capture larger consumer market shares, tabletop home consoles remain essential for applications requiring complex microfluidic chemistry, high-vacuum suction motors, or clinical laboratory-grade processing power. Stationary home hormone analyzers incorporate precision optical spectrophotometers, thermal incubators, and automated lateral flow cartridge readers, enabling quantitative, multi-analyte endocrine mapping that requires mechanical calibration beyond the capacity of handheld wands. Similarly, multi-user hospital-grade breast pump consoles offer high durability, closed-system cross-contamination barriers, and high-efficiency motors for mothers managing low milk supply, premature infants in the NICU, or multiples, serving as reliable medical devices rented or purchased through clinical channels.

By Technology and Connectivity

The U.S. Smart Women’s Health Devices Market by technology and connectivity is segmented into Bluetooth Low Energy (BLE) and Mobile App-Integrated, Cellular-Connected IoT and Cloud-Native, Edge-AI and Machine Learning Embedded, and Biosensors and Transdermal Microfluidics.

Bluetooth Low Energy (BLE) and Mobile App-Integrated
Bluetooth Low Energy (BLE) and mobile app-integrated systems represent the largest technology category, accounting for USD 3.24 billion in 2026, up from USD 2.08 billion in 2023, USD 2.40 billion in 2024, and USD 2.78 billion in 2025. The category is projected to reach USD 7.43 billion by 2032, expanding at a 14.83% CAGR from 2027 to 2032. This domain encompasses smart rings, wearable breast pumps, pelvic trainers, and fertility tracking devices that communicate wirelessly with native iOS and Android applications via BLE protocols.

The dominance of BLE integration lies in its universal compatibility with commercial consumer smartphones, high energy efficiency, and cost-effective hardware integration. BLE protocols allow medical device engineers to design ultra-compact biosensors that run on miniature coin-cell or rechargeable lithium-polymer batteries for days or weeks without recharging. Smartphone applications serve as the computational display and cloud gateway, translating raw hardware telemetry into actionable user interfaces, interactive biofeedback games, and longitudinal symptom diaries. Consumer-directed women’s health devices favor BLE architectures because they eliminate standalone cellular subscription fees for the user while leveraging the smartphone’s biometric security and Wi-Fi infrastructure to transmit synchronized health records into secure cloud repositories.

Cellular-Connected IoT and Cloud-Native
Cellular-connected IoT and cloud-native devices accounted for USD 2.17 billion in 2026, following historical figures of USD 1.32 billion in 2023, USD 1.55 billion in 2024, and USD 1.83 billion in 2025. This segment is projected to achieve USD 5.43 billion by 2032, growing at a 16.52% CAGR from 2027 to 2032. Products include remote obstetrical monitoring patches, smart blood pressure monitors, and gestational diabetes hubs equipped with integrated eSIM cards that connect directly to commercial 4G LTE-M and 5G narrowband IoT (NB-IoT) cellular networks.

Cellular-connected architectures represent the standard for prescription-grade medical devices and clinical remote patient monitoring programs. A recurring point of failure in remote patient monitoring has been patient friction during Bluetooth pairing, home Wi-Fi configuration, and smartphone operating system updates. By embedding dedicated cellular modems directly into device hardware, manufacturers enable zero-configuration, out-of-the-box operation. When an expectant mother with preeclampsia unboxes a cellular blood pressure cuff or applies a continuous CTG patch, the device transmits encrypted physiological measurements to the clinic’s cloud platform upon data capture. This streamlined data flow eliminates technical barriers for elderly, rural, or non-tech-savvy patients, ensuring consistent clinical data transmission and compliance with Medicare and commercial RPM billing thresholds.

Edge-AI and Machine Learning Embedded
Edge-AI and machine learning embedded devices accounted for USD 1.50 billion in 2026, having grown from USD 0.89 billion in 2023, USD 1.05 billion in 2024, and USD 1.25 billion in 2025. By 2032, the category is projected to reach USD 3.82 billion, reflecting a 16.86% CAGR from 2027 to 2032. This technology segment includes handheld colposcopes with real-time neural network lesion classification, wireless cardiotocography patches with automated maternal-fetal signal separation, smart pelvic trainers with dynamic muscle fatigue compensation, and wearable breast ultrasound devices with automated lesion localization.

Edge-AI represents the fastest-growing technology segment within the smart women’s health devices market, driven by the clinical demand for immediate, reliable diagnostic and therapeutic decision-making without reliance on persistent cloud connectivity. Integrating neural processing units (NPUs) and micro-machine learning algorithms directly onto hardware silicon allows these devices to process complex, high-bandwidth physiological data locally with sub-second latency. In intrapartum fetal monitoring, edge-AI algorithms continuously filter out motion artifacts and maternal cardiac electrical interference from raw acoustic or electromyographic signals, outputting clean, validated fetal heart rate tracings. In point-of-care cervical colposcopy, edge-AI models cross-examine optical tissue reflections against clinical image databases, highlighting suspicious margins for biopsy in real time, expanding clinical utility for general practitioners and mid-level clinicians.

Biosensors and Transdermal Microfluidics
Biosensors and transdermal microfluidics generated USD 0.77 billion in 2026, up from historical levels of USD 0.56 billion in 2023, USD 0.62 billion in 2024, and USD 0.69 billion in 2025. The segment is on track to achieve USD 1.56 billion by 2032, exhibiting a 12.49% CAGR from 2027 to 2032. Products include optical photoplethysmography sensor arrays, electrochemical transdermal hormone monitoring patches, microfluidic saliva and urine assay cartridges, and continuous glucose monitors (CGM) calibrated for gestational diabetes.

This technology group represents an essential clinical sensing foundation that translates raw biochemistry into digital diagnostic signals. The development of enzymatic and aptamer-based electrochemical sensors has enabled continuous or semi-continuous monitoring of circulating hormones, glucose, and inflammatory markers through interstitial fluid or micro-droplets of biological fluids. Advanced microfluidic cartridges incorporate capillary-driven fluidic channels and lyophilized reagents that execute multi-step immunoassay chemistries within minutes of sample application. These biosensing architectures eliminate the delay of central laboratory processing, allowing women and their healthcare providers to track acute endocrine transitions, confirm ovulatory success, and maintain glycemic control during high-risk pregnancies.

By End User

The U.S. Smart Women’s Health Devices Market by end user is segmented into Direct-to-Consumer and Home Healthcare, Hospitals, Birthing Centers, and Labor-and-Delivery Units, Obstetrics, Gynecology, and Urogynecology Specialty Clinics, and Ambulatory Surgical Centers and Telehealth Providers.

Direct-to-Consumer and Home Healthcare
Direct-to-consumer and home healthcare represents the largest end-user category, accounting for USD 3.38 billion in 2026, following historical figures of USD 2.11 billion in 2023, USD 2.45 billion in 2024, and USD 2.87 billion in 2025. The category is projected to reach USD 7.97 billion by 2032, expanding at a 15.37% CAGR from 2027 to 2032. This segment encompasses consumer-directed retail purchasing, e-commerce storefronts, specialized pharmacy fulfillment, and employer-sponsored corporate wellness platforms.

The commercial leadership of this end-user segment is sustained by female consumer autonomy, increased willingness to pay out-of-pocket for premium personal health hardware, and the broad eligibility of women’s health devices for HSA and FSA reimbursement. Female consumers actively seek over-the-counter connected devices for fertility tracking, lactation, pelvic wellness, and perimenopausal support, sidestepping the administrative hurdles of traditional clinical referral pathways. Medtech manufacturers capitalize on this direct engagement through subscription-based monetization models that bundle upfront hardware sales with ongoing access to personalized analytics, content libraries, and virtual coaching. Concurrently, certified home health agencies and visiting postpartum nursing services are expanding fleet procurement of cellular-connected maternal diagnostic kits to provide structured home healthcare for postpartum mothers recovering from cesarean deliveries or severe preeclampsia.

Hospitals, Birthing Centers, and Labor-and-Delivery Units
Hospitals, birthing centers, and labor-and-delivery units accounted for USD 2.11 billion in 2026, up from historical levels of USD 1.34 billion in 2023, USD 1.55 billion in 2024, and USD 1.80 billion in 2025. The segment is on track to reach USD 4.96 billion by 2032, advancing at a 15.31% CAGR from 2027 to 2032. This institutional category comprises non-profit health systems, for-profit hospital networks, municipal public hospitals, and independent regional birthing facilities.

Hospitals represent major commercial purchasers of capital-intensive, high-acuity smart women’s health systems, including enterprise wireless fetal-maternal telemetry networks, central nursing surveillance hubs, hospital-grade multi-user smart lactation stations, and point-of-care digital colposcopy fleets. Hospital capital procurement behavior is governed by group purchasing organization (GPO) contracts, electronic health record interoperability requirements, and patient safety quality metrics under the CMS Hospital Readmissions Reduction Program. Birthing centers and tertiary maternity hospitals are systematically retiring legacy wired fetal monitors in favor of cable-free, patch-based telemetry platforms that provide laboring patients with freedom of movement while ensuring continuous clinical data transmission to centralized labor-and-delivery telemetry walls.

Obstetrics, Gynecology, and Urogynecology Specialty Clinics
Obstetrics, gynecology, and urogynecology specialty clinics generated USD 1.50 billion in 2026, having grown from USD 0.94 billion in 2023, USD 1.09 billion in 2024, and USD 1.28 billion in 2025. By 2032, the category is projected to achieve USD 3.65 billion, demonstrating a 15.98% CAGR from 2027 to 2032. This clinical segment includes independent physician practices, consolidated specialty medical groups, academic OB/GYN outpatient clinics, and private urogynecology centers.

Specialty clinics serve as the primary clinical gatekeepers and prescribing authorities for prescription-grade smart women’s health devices. Practice revenue models have shifted toward value-based care and proactive chronic disease management, incentivizing specialty clinicians to deploy connected devices that generate remote physiologic monitoring and remote therapeutic monitoring revenues. Urogynecologists routinely prescribe smart pelvic biofeedback devices, tracking patient adherence and muscular recovery through cloud-based clinician portals between outpatient appointments. Maternal-fetal medicine subspecialists deploy connected blood pressure monitors and ambulatory CTG patches to manage high-risk pregnancies, conducting data-informed telehealth consultations that optimize in-clinic schedule capacity and reduce avoidable clinic crowding.

Ambulatory Surgical Centers and Telehealth Providers
Ambulatory surgical centers (ASCs) and telehealth providers accounted for USD 0.69 billion in 2026, following historical revenues of USD 0.46 billion in 2023, USD 0.53 billion in 2024, and USD 0.60 billion in 2025. The segment is projected to reach USD 1.66 billion by 2032, exhibiting a 15.76% CAGR from 2027 to 2032. This group includes specialized outpatient gynecological surgery centers, virtual-first women’s digital health platforms, hybrid clinical networks, and direct-to-consumer telemedicine providers.

The rapid growth of this segment reflects the expansion of virtual-first female healthcare delivery models that integrate physical smart diagnostic hardware into decentralized telehealth workflows. Telehealth platforms provide continuous clinical services spanning fertility workups, virtual prenatal care, postpartum recovery, and menopause management. Rather than relying entirely on patient-reported subjective symptoms, these digital providers ship connected medical kits—including cellular blood pressure cuffs, smart urine biomarker readers, and digital fetal dopplers—directly to the patient’s home. Device-derived data is ingested into the virtual provider’s proprietary clinical operating system, enabling physicians to make data-informed clinical decisions during synchronous video visits. Simultaneously, ambulatory surgical centers utilize handheld diagnostic colposcopes and point-of-care ultrasound devices to streamline pre-operative assessments and post-operative recovery monitoring for outpatient gynecological surgeries.

Regional Insights: Where the Market is Growing Fastest

The U.S. Smart Women’s Health Devices Market is geographically segmented into four primary commercial regions: the South, the West, the Midwest, and the Northeast. Regional market performance is governed by underlying structural dynamics, including total female population density, regional birth rates and maternal mortality indices, commercial and Medicaid payer reimbursement landscapes, private and corporate healthcare system density, the proliferation of virtual-first women’s health startups, and state-level legislative mandates regarding maternal healthcare equity and breast density notification.

South

The South represents the largest overall commercial regional market for smart women’s health devices in the United States, generating USD 2.87 billion in 2026, up from historical levels of USD 1.79 billion in 2023, USD 2.08 billion in 2024, and USD 2.43 billion in 2025. The Southern regional market is projected to reach USD 6.94 billion by 2032, expanding at a 15.85% CAGR from 2027 to 2032. The South’s commercial revenue leadership is anchored by its vast population, accounting for nearly 40% of the total U.S. population, nation-leading annual birth volumes, and an acute clinical need to resolve disparities in maternal health outcomes and rural healthcare access. The Southern region records some of the highest maternal morbidity and mortality ratios in the country, alongside widespread obstetrical unit closures across rural counties—often termed “maternity care deserts.” These structural healthcare access deficits have compelled state health authorities, Medicaid managed care organizations, and large hospital networks to adopt decentralized maternal health monitoring devices, cellular-connected remote blood pressure cuffs, and home-use fetal telemetry patches to maintain clinical surveillance over high-risk pregnant women across broad geographic territories.

Texas represents the primary economic engine within the Southern smart women’s health devices landscape, supported by an expanding population, annual live births exceeding 380,000, and major medical centers. Major metropolitan areas, including Houston, Dallas-Fort Worth, Austin, and San Antonio, host extensive academic medical systems, including the Texas Medical Center, Texas Children’s Hospital Pavilion for Women, and UT Southwestern Medical Center, which represent high-volume institutional buyers of connected maternal-fetal telemetry fleets, smart neonatal lactation stations, and point-of-care cervical colposcopy platforms. Simultaneously, the state faces maternal care shortages across its rural counties, driving Texas Medicaid managed care programs to execute statewide remote patient monitoring pilot contracts for expectant mothers with chronic hypertension or gestational diabetes. Private obstetrical practices across the expanding suburban corridors of North Texas and Central Texas exhibit high adoption of smart pelvic floor rehabilitation devices and connected fertility biosensors, supported by private insurance coverage and corporate health benefits.

Florida represents the second-largest state market within the South, distinguished by high disposable household incomes in metropolitan regions, an expanding reproductive demographic, and an extensive population of post-menopausal women. Metros such as Miami, Fort Lauderdale, Tampa-St. Petersburg, and Orlando exhibit dense concentrations of private OB/GYN specialty clinics, urogynecology centers, and ambulatory surgery networks. Florida’s demographic profile generates balanced demand spanning the entire women’s health continuum. High annual birth volumes across South and Central Florida drive consistent procurement of smart wearable breast pumps and wireless intrapartum cardiotocography systems, while the state’s extensive mature female demographic establishes it as the country’s leading regional market for smart pelvic floor biofeedback trainers, transcutaneous tibial nerve stimulators for overactive bladder, and connected bone mineral density screening devices. Furthermore, Florida’s favorable business climate has attracted virtual-first women’s health providers and specialty telemedicine hubs that distribute connected diagnostic kits directly to patients across the state.

North Carolina and Georgia represent rapidly expanding female health technology corridors fueled by population influxes, expanding technology centers, and major academic medical infrastructure. In North Carolina, the Research Triangle region—encompassing Raleigh, Durham, and Chapel Hill—alongside the Charlotte metropolitan area, supports advanced clinical research and adoption across Duke Health, UNC Health, and Atrium Health. These institutions have integrated cellular-connected remote patient monitoring platforms into routine prenatal care pathways, deploying smart blood pressure cuffs and fetal telemetry patches to combat maternal mortality across rural and urban patient cohorts. Georgia, anchored by the Atlanta metropolitan area, features substantial commercial demand supported by Emory Healthcare, Piedmont Healthcare, and the Morehouse School of Medicine Center for Maternal Health Equity. Georgia’s Department of Community Health has expanded postpartum Medicaid coverage to a full year post-delivery, unlocking substantial reimbursement liquidity for connected postpartum hypertension monitoring devices and connected pelvic rehabilitation systems across urban and underserved rural clinics.

Virginia, Tennessee, and the broader Gulf Coast states—including Louisiana, Alabama, and Mississippi—sustain substantial demand driven by health equity initiatives and targeted clinical modernization grants. Northern Virginia, functioning as an affluent suburb of Washington, D.C., exhibits high per-capita consumer spending on premium direct-to-consumer fertility wearables, smart rings, and connected breast pumps. In Tennessee, Nashville’s position as a national healthcare corporate management hub has accelerated the clinical integration of smart women’s devices across large hospital operating chains, such as HCA Healthcare. In the Gulf Coast states, where maternal mortality rates and rural hospital closures are among the highest nationally, state-sponsored maternal health coalitions and federally qualified health centers (FQHCs) are deploying cellular-connected remote obstetrical monitoring bundles to high-risk patients, establishing vital diagnostic links between rural mothers and maternal-fetal medicine specialists in tertiary medical centers.

The commercial landscape across the South is defined by the operational contrast between affluent metropolitan health networks and under-resourced rural healthcare systems. While urban specialty centers aggressively procure edge-AI digital colposcopes and high-end wireless fetal CTG systems, rural clinics require durable, zero-configuration cellular-connected devices that function reliably across areas with limited broadband access. Medical device manufacturers that succeed in the South maintain hybrid distribution strategies, pairing direct enterprise sales to large hospital chains and GPOs with Medicaid managed care contracting and FQHC distribution partnerships, ensuring comprehensive coverage across both commercial and publicly funded female healthcare sectors.

West

The West represents the second-largest and technically sophisticated regional market, accounting for USD 2.10 billion in 2026, following historical revenues of USD 1.31 billion in 2023, USD 1.52 billion in 2024, and USD 1.78 billion in 2025. The Western market is projected to reach USD 5.06 billion by 2032, demonstrating a 15.79% CAGR from 2027 to 2032. The region’s strong market position is propelled by early clinical technology adoption, high commercial health insurance reimbursement rates, progressive state legislative mandates supporting reproductive and maternal healthcare access, high disposable household incomes, and a dense concentration of digital health venture capital, medical device innovators, and consumer technology conglomerates.

California represents the primary commercial anchor of the Western region and the largest single state market for smart women’s health devices in the United States. Supported by a female population exceeding 19 million, California’s healthcare ecosystem is characterized by rapid clinical adoption, integrated healthcare delivery networks, and proactive maternal quality programs spearheaded by the California Maternal Quality Care Collaborative (CMQCC). The Greater Los Angeles basin, Orange County, San Diego, and the San Francisco Bay Area support world-renowned academic medical centers, including Stanford Medicine, UCSF Health, Cedars-Sinai Medical Center, and UCLA Health, alongside massive integrated managed care systems such as Kaiser Permanente. Healthcare providers throughout California are rapid adopters of hospital-grade wireless fetal monitoring patches, cellular-connected remote preeclampsia surveillance platforms, and smart automated breast ultrasound devices for women with dense breast tissue. Furthermore, California’s affluent, tech-forward consumer base drives nation-leading sales of direct-to-consumer smart fertility rings, connected wearable breast pumps, and app-integrated pelvic floor biofeedback trainers.

Washington and Oregon represent mature, progressive female healthcare markets characterized by high per-capita healthcare spending, strong public health infrastructure, and comprehensive commercial insurance coverage mandates. The Seattle metropolitan area, alongside Portland, Oregon, exhibits high consumer adoption of connected health hardware and digital therapeutics. Regional integrated health networks, including Providence Health, Swedish Medical Center, and Oregon Health & Science University (OHSU), have institutionalized virtual prenatal and postpartum care models, prescribing connected blood pressure cuffs and smart fetal monitors to patients across urban and remote Pacific Northwest communities. Furthermore, employers in the region’s dominant technology corridor routinely offer comprehensive corporate family-building and female wellness benefits that fully subsidize smart lactation pumps, continuous ovulation biosensors, and home pelvic therapy devices for their workforces.

Colorado, Arizona, and Utah represent dynamic, fast-growing interior Western markets driven by significant population in-migration, expanding corporate hubs, and high birth rates. Colorado’s Front Range corridor—stretching from Fort Collins through Denver to Colorado Springs—represents an important regional hub for medical technology innovation and clinical excellence, anchored by the University of Colorado Anschutz Medical Campus. Healthcare practices across Colorado report high patient engagement with connected women’s health devices, particularly in outpatient urogynecology and sports-related female pelvic floor rehabilitation. Arizona, anchored by the Phoenix-Scottsdale metropolitan area, features an expanding maternal health market alongside a large mature female population that drives heavy clinical utilization of connected pelvic floor stimulators, smart incontinence management devices, and non-invasive osteoporosis screening tools. Utah, distinguished by one of the highest birth rates in the United States, exhibits high per-capita demand for connected maternal-fetal monitors, smart wearable breast pumps, and home ovulation tracking systems, supported by integrated health systems such as Intermountain Health. Nevada, Idaho, and the Mountain West states contribute additional market velocity as rural health networks deploy cellular remote monitoring to bridge geographic distances between expecting mothers and regional delivery centers.

The commercial environment across the West is defined by high consumer expectations for data privacy, clinical trial validation, and seamless digital interoperability. Female patients in this region demand strict compliance with state privacy frameworks, such as the California Consumer Privacy Act (CCPA) and specialized reproductive health data protection statutes, compelling device manufacturers to implement end-to-end data encryption, local edge-processing architectures, and transparent data consent protocols. Medtech manufacturers targeting the Western market prioritize seamless API integration with Epic and Cerner EHR platforms, allowing clinician-prescribed device metrics to flow directly into medical charts, thereby securing clinical buy-in from integrated delivery networks and tech-forward physician groups.

Midwest

The Midwest represents a mature, highly resilient market for smart women’s health devices, generating USD 1.51 billion in 2026, up from historical levels of USD 0.97 billion in 2023, USD 1.12 billion in 2024, and USD 1.30 billion in 2025. The Midwestern market is projected to reach USD 3.47 billion by 2032, expanding at a 14.88% CAGR from 2027 to 2032. The region’s commercial performance is anchored by major academic health systems, extensive non-profit healthcare networks, and a balanced demographic profile spanning densely populated industrial metropolitan centers and expansive agricultural rural communities. Midwestern clinical procurement is characterized by disciplined capital budgeting, rigorous total-cost-of-ownership evaluations, and a strong preference for devices that demonstrate measurable clinical efficacy, reduced hospital readmissions, and tangible workflow efficiencies for nursing staff.

Illinois and Ohio represent the primary revenue drivers within the Midwestern smart women’s health devices landscape. The Chicago metropolitan area encompasses one of the densest and most lucrative healthcare markets in the nation, home to renowned institutions including Northwestern Medicine, Rush University Medical Center, and the University of Chicago Medicine. Chicago healthcare systems have established standardized clinical pathways for high-risk obstetrical care, deploying cellular remote blood pressure monitoring programs to reduce maternal morbidity disparities across the city’s South and West sides. Practices in this urban corridor demonstrate high prescription volumes for smart pelvic floor biofeedback devices, connected fertility monitors, and hospital-grade wearable breast pumps. Ohio features an exceptionally strong healthcare delivery infrastructure, anchored by the Cleveland Clinic, OhioHealth, and The Ohio State University Wexner Medical Center. Ohio health systems have invested heavily in centralized clinical telemetry command centers, driving enterprise procurement of wireless intrapartum fetal monitoring patches and cloud-connected maternal surveillance platforms that integrate directly into hospital-wide electronic medical record systems.

Michigan, Indiana, and Wisconsin provide substantial market demand spanning urban clinical medical centers and community hospital networks. Michigan’s healthcare market, centered on Detroit, Ann Arbor, and Grand Rapids, exhibits robust adoption across academic centers such as Michigan Medicine (University of Michigan) and integrated networks like Henry Ford Health and Corewell Health. These institutions have pioneered decentralized clinical trial protocols and remote patient monitoring programs for pregnant and postpartum patients, driving consistent hardware procurement. Indiana features major corporate healthcare organizations, a thriving life sciences manufacturing corridor, and Indiana University Health, which serves as a major clinical referral center for complex maternal-fetal medicine across the state. Wisconsin represents a key center for healthcare software innovation and clinical excellence, home to Epic Systems and leading health systems such as Advocate Aurora Health and UW Health. The proximity of Epic’s headquarters has accelerated the pilot deployment of smart women’s health devices with native FHIR-based EHR integration, establishing Wisconsin clinics as early adopters of automated device data ingestion.

Minnesota, Missouri, Iowa, and the Plains States—including Kansas, Nebraska, and the Dakotas—represent critical centers of clinical research, healthcare system management, and rural healthcare delivery. Minnesota is home to the Mayo Clinic in Rochester, a globally recognized institution that sets clinical practice standards and conducts rigorous clinical evaluations of emerging female health hardware, including edge-AI digital colposcopes and non-invasive continuous hormone sensors. Minneapolis-St. Paul supports a dense concentration of medical device development, fostering a favorable regional climate for clinical trial recruitment and early commercialization. Missouri, anchored by BJC HealthCare and SSM Health in St. Louis and Saint Luke’s Health System in Kansas City, demonstrates strong clinical demand for connected maternal monitoring and ambulatory pelvic health platforms. In Iowa and the agricultural Plains states, regional health systems utilize cellular-connected remote monitoring platforms to provide continuous prenatal and postpartum clinical surveillance across rural communities facing shortages of practicing obstetricians.

Procurement behavior across the Midwest emphasizes economic accountability and clinical durability. Hospital purchasing committees, value analysis teams, and independent physician associations demand peer-reviewed clinical validation, published health economics and outcomes research (HEOR) data, and seamless compatibility with established clinical workflows before approving device formulary additions. Manufacturers achieve superior commercial conversion across the Midwest by offering structured risk-sharing arrangements, transparent clinical training programs, and dedicated integration support that demonstrates how smart devices reduce 30-day maternal hospital readmissions and lower emergency department utilization.

Northeast

The Northeast represents a concentrated, high-value, and clinically sophisticated regional market, accounting for USD 1.20 billion in 2026, having grown from USD 0.78 billion in 2023, USD 0.90 billion in 2024, and USD 1.04 billion in 2025. The Northeastern market is projected to reach USD 2.77 billion by 2032, demonstrating a 14.95% CAGR from 2027 to 2032. While the Northeast is geographically more compact than the South or Midwest, it features the nation’s highest geographic density of elite academic medical centers, Ivy League teaching hospitals, specialized urogynecological and cancer institutes, and affluent consumer demographics with high healthcare spending and high rates of private health insurance coverage.

New York represents the economic and clinical cornerstone of the Northeastern smart women’s health devices market, driven by the massive concentration of healthcare infrastructure and population across the New York City metropolitan area, Long Island, and Westchester County, complemented by practice networks across upstate New York. Healthcare systems in New York City—including NewYork-Presbyterian Hospital, Mount Sinai Health System, NYU Langone Health, and Memorial Sloan Kettering Cancer Center—operate at the cutting edge of clinical care and medical research. New York City’s hospital networks invest heavily in wireless intrapartum maternal-fetal monitoring systems, cloud-connected neonatal and postpartum care hardware, and handheld AI colposcopy platforms to serve diverse patient populations. Furthermore, New York State’s comprehensive legislative mandates covering reproductive health, postpartum Medicaid extension, and commercial insurance coverage for lactation consultants and breast pumps have established a highly favorable payer environment that accelerates device reimbursement and clinical distribution.

Pennsylvania represents the second-largest state market within the Northeast, supported by major academic medical centers and healthcare networks in Philadelphia and Pittsburgh. The University of Pennsylvania Health System (Penn Medicine), Jefferson Health, and the Temple University Health System in Philadelphia manage high-volume labor-and-delivery units and specialized maternal-fetal medicine clinics that actively deploy cellular remote patient monitoring for high-risk pregnancies and postpartum hypertension. In Western Pennsylvania, the University of Pittsburgh Medical Center (UPMC) and its renowned UPMC Magee-Womens Hospital represent globally preeminent centers for gynecological and obstetrical clinical care. UPMC Magee-Womens Hospital serves as an institutional proving ground for advanced women’s health devices, driving high-volume procurement of point-of-care digital colposcopes, automated breast ultrasound systems, and connected pelvic floor rehabilitation platforms.

Massachusetts, New Jersey, and Connecticut represent exceptionally affluent, scientifically rigorous markets characterized by high health literacy, superior commercial insurance coverage, and strong medical research environments. The Greater Boston metropolitan area, anchored by Mass General Brigham (comprising Massachusetts General Hospital and Brigham and Women’s Hospital), Beth Israel Deaconess Medical Center, and Boston Children’s Hospital, represents a premier global hub for biomedical innovation, clinical trials, and clinical standard-setting. Boston’s clinical community rapidly validates and adopts emerging female health devices, including continuous endocrine monitoring patches, wearable thermal neuromodulators for menopause, and prescription-grade pelvic floor trainers. New Jersey’s dense healthcare network and pharmaceutical corridor, alongside Connecticut’s affluent Fairfield County and the Yale New Haven Health system, exhibit high consumer out-of-pocket spending on premium direct-to-consumer fertility wearables and hands-free smart breast pumps, supported by high private practice adoption of remote physiologic monitoring codes.

Maine, New Hampshire, Vermont, and Rhode Island complete the Northeastern landscape, representing stable markets with high health insurance coverage rates and well-coordinated community health networks. Northern New England health systems, including Dartmouth Health in New Hampshire and the University of Vermont Health Network, actively deploy cellular-connected maternal health monitoring devices to manage obstetrical care across rural and mountainous populations, ensuring that expectant mothers maintain direct telemetry connections to regional perinatal referral centers.

The commercial environment across the Northeast is defined by clinical evidence requirements and institutional review standards. With an extraordinary concentration of board-certified subspecialists in maternal-fetal medicine, female pelvic medicine and reconstructive surgery (FPMRS), and gynecologic oncology, purchasing decisions are guided by peer-reviewed clinical trial data, published safety metrics, and formal society endorsements from ACOG, AUGS, and the Society for Maternal-Fetal Medicine (SMFM). Medical device manufacturers achieve their highest penetration in the Northeast by engaging academic thought leaders, publishing robust randomized controlled trial results, and ensuring compliance with stringent electrical safety, biocompatibility, and cybersecurity standards.

Key Market Players

The competitive landscape of the U.S. Smart Women’s Health Devices Market is characterized by a dynamic interplay between diversified medical technology conglomerates expanding their dedicated female health divisions, specialized clinical femtech device manufacturers, and agile, venture-backed digital health innovators.

Highly relevant players operating in the U.S. smart women’s health devices industry include:

GE HealthCare Technologies Inc.
Koninklijke Philips N.V. (Philips Healthcare)
Medtronic plc
Hologic, Inc.
Nuvo Group D.G. Ltd.
Willow Innovations, Inc.
Elvie (Chiaro Technology Ltd.)
Bloomlife Inc.
Ava AG (FemTec Health)
Oura Health Oy
INVO Bioscience, Inc.
Renovia Inc.
Perifit SAS
MaternalDx Inc.
MobileODT Ltd.

GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. represents a global benchmark in obstetrical imaging and intrapartum maternal-fetal surveillance, commanding an extensive installed base of cardiotocography systems, central labor-and-delivery monitoring software, and automated breast ultrasound platforms across American hospitals. The company differentiates itself through its proprietary Centricity Perinatal and AW workstation software ecosystems, which seamlessly link bedside wireless maternal-fetal telemetry hardware with hospital enterprise electronic health records, automated clinical decision-support algorithms, and centralized nursing telemetry walls. GE HealthCare’s strategic emphasis centers on embedding artificial intelligence into clinical imaging and obstetrical workflows, expanding its automated breast ultrasound (Invenia ABUS) product lines for women with dense breast tissue, and commercializing wireless, cable-free intrapartum fetal monitoring solutions that provide laboring mothers with mobility while maintaining continuous telemetry fidelity.

Koninklijke Philips N.V. (Philips Healthcare)

Koninklijke Philips N.V. maintains a formidable presence across hospital and ambulatory women’s health environments, combining clinical-grade fetal-maternal monitors, consumer mother-and-child care platforms (Philips Avent), and enterprise clinical informatics. Philips’ competitive advantage lies in its capacity to span the entire care continuum, from professional labor-and-delivery monitoring suites (Avalon fetal monitor series) utilizing advanced cable-free acoustic and capacitive transducer technology, to connected postpartum maternal health platforms. Philips has prioritized remote patient monitoring, commercializing cellular-connected fetal-maternal surveillance solutions that allow obstetricians to track high-risk pregnancies remotely, directly addressing maternal health disparities and clinical staffing shortages across regional healthcare networks.

Medtronic plc

Medtronic plc is a dominant force in advanced urogynecological and female pelvic health medical devices, leading the market in sacral neuromodulation (SNM) and targeted peripheral nerve stimulation systems for overactive bladder, urge urinary incontinence, and chronic fecal incontinence. Through its InterStim system portfolio, which includes miniaturized, recharge-free, and rechargeable smart implantable neurostimulators with smart programmer interfaces, Medtronic sets the gold standard for refractory pelvic floor dysfunction therapy. The company continues to advance its female pelvic health footprint by developing minimally invasive, smart implantable neuromodulation technologies and connected patient programming wands that utilize Bluetooth connectivity to allow patients and clinicians to optimize stimulation parameters via secure mobile interfaces.

Hologic, Inc.

Hologic, Inc. is the undisputed global and U.S. market leader in female diagnostic imaging, cervical cancer screening, and minimally invasive gynecological surgical hardware. The company’s flagship Dimensions 3D Mammography (breast tomosynthesis) systems represent the clinical standard of care for early breast cancer detection across American imaging centers. Hologic differentiates its commercial portfolio by integrating sophisticated machine learning and deep learning algorithms (Genius AI) directly into mammography workstations to assist radiologists in detecting subtle malignant architectural distortions. In gynecological health, Hologic provides the ThinPrep liquid-based cytology and Pap test ecosystem, the NovaSure endometrial ablation system, and the MyoSure hysteroscopic tissue removal system, reinforcing its institutional procurement contracts across hospital operating rooms and outpatient surgery centers nationwide.

Nuvo Group D.G. Ltd.

Nuvo Group D.G. Ltd. represents a pioneering innovator in prescription remote maternal-fetal surveillance through its FDA-cleared INVU platform. The INVU solution transforms traditional obstetrical monitoring by replacing legacy Doppler ultrasound belts with an advanced, sensor-dense maternal abdominal band that captures continuous maternal and fetal electrocardiograms, alongside uterine electromyography. The band transmits raw physiological data to cloud-based neural networks that separate maternal and fetal heart rates with clinical accuracy matching hospital bedside CTG machines. Nuvo Group’s commercial strategy targets maternal-fetal medicine practices, health systems, and virtual obstetrical networks, providing a turnkey remote monitoring system that enables expectant mothers to complete comprehensive antepartum non-stress tests (NSTs) from home, reimbursed under established remote patient monitoring and fetal monitoring CPT codes.

Willow Innovations, Inc.

Willow Innovations, Inc. revolutionized the lactation technology landscape by engineering the world’s first completely mobile, in-bra, spill-proof wearable breast pump. Willow’s product portfolio, led by the Willow 360 and Willow Go smart pumps, features miniaturized continuous suction motors, anatomical liquid-silicone flanges, and proprietary continuous-pumping mechanics that allow milk expression in any physical orientation without leakage. Willow differentiates itself through its mobile app integration, which utilizes optical sensors to provide real-time milk volume tracking, session history, and lactation coaching. The company has successfully executed a dual-distribution commercial strategy, combining direct-to-consumer e-commerce sales with extensive coverage across commercial health insurance plans, medical supply providers (DME), and corporate employer lactation benefit programs.

Elvie (Chiaro Technology Ltd.)

Elvie is an internationally recognized female technology pioneer that transformed consumer and clinical perceptions of women’s personal health hardware. Elvie established market leadership through the launch of the Elvie Pump, an ultra-quiet, wearable in-bra smart breast pump utilizing proprietary piezoelectric pumping mechanisms, and the Elvie Trainer, an FDA-cleared smart intra-vaginal pelvic floor rehabilitation device. The Elvie Trainer incorporates multi-axis force and motion sensors that detect faulty pelvic contraction biomechanics—such as downward bearing down—and provides real-time visual biofeedback on an interactive smartphone application. Elvie’s products command premium pricing and consumer loyalty, distributed widely across high-end retail, specialty medical distributors, and commercial insurance reimbursement networks.

Bloomlife Inc.

Bloomlife Inc. operates at the forefront of maternal-fetal clinical biosensing and predictive digital obstetrics. The company has engineered medical-grade, skin-adherent physiological sensor patches that attach to the pregnant abdomen to continuously record electrophysiological activity, maternal heart rate, heart rate variability, and uterine contractions. Bloomlife’s proprietary signal-processing algorithms analyze electrical contraction wave patterns to distinguish between benign Braxton Hicks contractions and true preterm labor contractions. By building vast databases of maternal-fetal electrophysiological signatures, Bloomlife is developing predictive artificial intelligence models that identify early biomarkers of pregnancy complications, including fetal growth restriction and impending preterm delivery, positioning the company as an essential technology partner for health systems seeking to reduce avoidable NICU admissions.

Ava AG (FemTec Health)

Ava AG, operating within the FemTec Health healthcare ecosystem, is a pioneer in continuous biometric fertility tracking and cycle monitoring. Ava developed the FDA-cleared Ava Fertility Plus sensor bracelet, which is worn during sleep to capture continuous skin temperature, resting pulse rate, heart rate variability, perfusion index, and breathing rate. Ava’s machine learning algorithms process these multi-parameter biometric streams to identify the subtle physiological shifts triggered by rising estradiol and luteinizing hormone levels, prospective detecting a woman’s five-day fertile window in real time with high clinical precision. The company targets both direct-to-consumer family planning markets and clinical reproductive health networks, providing an objective, non-invasive digital alternative to manual urine strip testing.

Oura Health Oy

Oura Health Oy has established a dominant market position within female physiological tracking through its smart ring hardware, the Oura Ring. Featuring miniature research-grade infrared PPG sensors, negative temperature coefficient (NTC) thermistors measuring body temperature fluctuations down to 0.01 degrees Celsius, and 3D accelerometers, the Oura Ring continuously maps circadian and infradian temperature profiles. Oura has developed dedicated female health algorithms, including Cycle Insights, which predicts menstrual phases and fertile windows by analyzing overnight temperature shifts. Furthermore, through strategic commercial partnerships with leading women’s health digital therapeutics, including Natural Cycles (the first FDA-cleared digital birth control application), Oura provides an automated, medical-grade biometric data capture gateway that eliminates the need for manual morning oral thermometry.

INVO Bioscience, Inc.

INVO Bioscience, Inc. represents a disruptive medical device company dedicated to expanding the accessibility and affordability of assisted reproductive technology (ART) through its proprietary INVOcell system. The INVOcell is an FDA-cleared, patented, novel intravaginal culture device that enables the fertilization and early embryonic incubation to take place directly within the woman’s vaginal cavity, rather than in an expensive, complex in vitro laboratory incubator. By utilizing the patient’s own body as a natural biological incubator to maintain optimal physiological temperature, gas balance, and pH, the INVOcell technology significantly reduces the capital and operational costs associated with conventional IVF cycles. The company is actively opening specialized INVO Centers and partnering with private reproductive endocrinology practices across the United States to deliver accessible fertility care.

Renovia Inc.

Renovia Inc. is a clinical-stage medical technology company dedicated to developing digital therapeutics and diagnostic platforms for female pelvic floor disorders. Renovia commercialized the leva Pelvic Health System, an FDA-cleared, prescription-only medical device that utilizes high-precision dynamic motion sensor arrays embedded in a flexible vaginal probe to guide and document pelvic floor muscle training. The leva System captures real-time pelvic floor movement at sub-millimeter scales, ensuring that women perform correct levator ani upward displacement rather than Valsalva bearing down. Renovia has established peer-reviewed clinical trial validation, including large multi-center randomized controlled trials demonstrating superior therapeutic outcomes for female stress and urgency urinary incontinence, securing dedicated reimbursement coverage across commercial health plans and regional Medicare carriers.

Perifit SAS

Perifit SAS is an innovative European medical device manufacturer that has established a dominant market presence across the United States in connected pelvic health rehabilitation. The company manufactures the Perifit and Perifit+ smart pelvic floor trainers, which utilize proprietary dual-sensor technology comprising both intra-pelvic force transducers and positional displacement sensors. This dual-sensing architecture simultaneously measures the strength of the levator ani contractions and flags incorrect intra-abdominal bearing-down forces. Perifit gamifies pelvic therapy through an engaging mobile application, guiding patients through clinical rehabilitation protocols designed to treat stress incontinence, overactive bladder, and postpartum pelvic organ prolapse. The company has expanded its commercial portfolio into connected lactation devices, launching the Perifit Pump, an ultra-compact, high-performance wearable breast pump.

MaternalDx Inc.

MaternalDx Inc. is an emerging American medtech diagnostics enterprise focused on developing point-of-care, non-invasive microfluidic and molecular screening devices for life-threatening obstetrical conditions, particularly preeclampsia and fetal aneuploidy. The company’s primary clinical platform integrates capillary blood and saliva microfluidics with handheld optical analyzers, quantifying circulating angiogenic biomarkers, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), within minutes. By providing quantitative sFlt-1/PlGF ratio results directly within outpatient OB/GYN clinics, MaternalDx equips clinicians with immediate prognostic validation to predict the development of severe preeclampsia up to four weeks prior to clinical symptom onset, transforming maternal triage protocols across community and academic health systems.

MobileODT Ltd.

MobileODT Ltd. is a commercial-stage healthcare technology company that merges advanced optical engineering with visual artificial intelligence to enhance cervical cancer screening and colposcopy triage. The company’s flagship product, the EVA System, is an FDA-cleared, mobile, handheld digital colposcope equipped with cross-polarized light-emitting diodes, high-definition optical magnification, and cloud-connected tele-consultation capabilities. MobileODT incorporates its proprietary VisualCheck algorithm, an edge-AI software tool that analyzes digital cervical images and delivers an immediate, automated assessment of cervical dysplasia with accuracy matching expert colposcopists. The EVA System is widely deployed across American community health networks, FQHCs, academic hospital residency training clinics, and rural health departments to democratize access to high-quality cervical cancer screening and prevent missed cervical cancer diagnoses.

Recent Developments

The U.S. smart women’s health devices industry has undergone rapid corporate reorganization, clinical workflow integration, technological innovation, and regulatory expansion between 2024 and 2026.

A defining structural development has been the systematic integration of connected remote patient monitoring (RPM) platforms into standard obstetrical and gynecological clinical workflows, accelerated by updated clinical management guidelines from the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM). In 2024 and 2025, major regional health systems—including Kaiser Permanente, Advocate Health, HCA Healthcare, and Mass General Brigham—transitioned from small, exploratory RPM pilots toward enterprise-wide standardization of cellular-connected maternal health kits for all high-risk pregnancies. By establishing centralized perinatal remote monitoring hubs staffed by dedicated obstetrical nurses who track automated physiological alerts from home-based blood pressure monitors and wireless fetal patches, health systems have reported substantial reductions in postpartum readmissions for severe preeclampsia, alongside decreased rates of emergency room utilization during the antepartum period.

Strategic mergers, acquisitions, and cross-sector partnerships have reshaped competitive positioning across digital health, consumer wearables, and traditional medical device corporations. Major consumer technology conglomerates and leading wearable manufacturers have aggressively expanded their clinical credentials by acquiring or licensing proprietary femtech sensor patents, clinical-grade algorithms, and specialized digital therapeutic assets. Concurrently, traditional maternal-fetal medical device manufacturers have established strategic equity investments and co-development distribution agreements with venture-backed smart breast pump and pelvic trainer startups. These partnerships allow established medtech conglomerates to bundle smart home-use devices with their enterprise hospital capital equipment lines, presenting hospital purchasing committees with comprehensive, continuum-of-care procurement contracts spanning inpatient labor-and-delivery units, outpatient OB/GYN clinics, and home health environments.

Product innovation within artificial intelligence-driven diagnostic imaging has achieved unprecedented clinical commercialization between 2024 and 2026. The FDA Center for Devices and Radiological Health (CDRH) has granted multiple 510(k) clearances and De Novo classifications for edge-AI software modules embedded within handheld colposcopes, automated breast ultrasound systems, and patch-based fetal-maternal cardiotocography devices. In cervical cancer screening, the commercial deployment of handheld digital colposcopes with integrated visual AI algorithms has enabled primary care providers and nurse practitioners in community health centers to perform reliable cervical dysplasia risk-stratification at the point of care, eliminating the diagnostic delays and high loss-to-follow-up rates historically associated with secondary referrals to tertiary specialty centers. In breast imaging, automated handheld ultrasound scanners featuring deep learning lesion localization algorithms have established strong clinical penetration as standard supplemental screening devices for women with dense breast tissue, expanding early-stage tumor detection beyond traditional hospital mammography suites.

Wearable lactation hardware and smart breast pumps have experienced an engineering shift toward micro-piezoelectric air pumps, adaptive expression algorithms, and hands-free ergonomic designs. Between late 2024 and early 2026, several manufacturers introduced whisper-quiet, motor-integrated wearable pumps that fit discreetly inside standard nursing bras without requiring external tubing or collection bottles. These devices incorporate microfluidic optical sensors that continuously measure milk let-down velocity, dynamically adjusting suction cycle rhythms and vacuum levels to optimize maternal comfort and milk ejection reflexes. The commercial availability of these smart pumps has been supported by federal workplace lactation mandates under the PUMP Act, alongside the widespread inclusion of wearable smart pumps on commercial insurance formulary lists, lowering out-of-pocket acquisition hurdles for working mothers.

The regulatory and reimbursement landscape has simultaneously expanded coverage pathways for female-specific digital therapeutics and prescription-grade biofeedback hardware. Commercial payers representing over 120 million covered lives have established formal medical necessity coverage policies for prescription smart pelvic floor rehabilitation systems used in treating stress and urge urinary incontinence. Peer-reviewed randomized controlled trials published between 2024 and 2026 demonstrated that guided home-use smart pelvic biofeedback devices deliver clinical symptom improvement comparable to surgical intervention, providing payers with clinical and economic justification to reimburse these devices under existing CPT codes for pelvic muscle neuromuscular re-education (CPT 97032 and 97110), alongside specialized Remote Therapeutic Monitoring (RTM) codes (CPT 98975, 98977, 98980, and 98981).

Furthermore, wearable biometric sensors for continuous reproductive and hormonal monitoring have transitioned from consumer wellness applications into clinically validated medical devices. Innovative medtech developers and academic research centers have commercialized smart rings, continuous transdermal patches, and microfluidic saliva and urine analyzers capable of tracking ovulation, luteal phase adequacy, and perimenopausal endocrine transitions with laboratory-grade precision. These devices integrate multi-wavelength optical PPG sensors and ultra-sensitive temperature thermistors, utilizing neural networks to differentiate true ovulatory temperature surges from fever, alcohol consumption, or sleep disruption. By providing continuous, objective biological data streams directly to reproductive endocrinologists and gynecologists via secure cloud platforms, these platforms are streamlining fertility evaluations, optimizing assisted reproductive technology cycles, and modernizing the clinical management of perimenopause and menopause.

Conclusion

The U.S. Smart Women’s Health Devices Market Size & Share is positioned to expand from USD 7.68 billion in 2026 to approximately USD 18.24 billion by 2032, supported by a 15.51% CAGR from 2027 to 2032. Historical market development from USD 4.85 billion in 2023, USD 5.62 billion in 2024, and USD 6.55 billion in 2025 demonstrates the structural resilience, strong consumer demand, and rapid clinical adoption of female-specific medical hardware across macroeconomic cycles.

The underlying growth thesis is propelled by structural transformations across the American healthcare landscape. The national urgency to reverse maternal mortality and morbidity rates has elevated maternal-fetal remote monitoring from an elective pilot program into an institutional clinical priority. This priority is supported by the formal expansion of remote physiologic monitoring and remote therapeutic monitoring reimbursement codes by CMS and commercial payers, which provides health systems, independent physician groups, and virtual-first digital clinics with sustainable, recurring clinical revenue streams.

The commercial marketplace is defined by the migration away from adapted, male-normed medical devices toward purpose-engineered female healthcare hardware. Modern clinical practices and female consumers require specialized hardware incorporating sex-specific physiological algorithms, non-invasive transdermal and microfluidic biosensors, hands-free silent wearable architectures, high-resolution pelvic biomechanical feedback mechanisms, and edge artificial intelligence that delivers diagnostic accuracy at the point of care.

Connected maternal and fetal monitoring systems and smart wearable breast pumps will maintain revenue scale across product categories, driven by high birth volumes, workplace lactation mandates, and the shift toward decentralized high-risk obstetrical care. Concurrently, smart pelvic floor rehabilitation devices and connected fertility and ovulation trackers will capture substantial value through high-margin prescription therapeutic hardware, consumable fluidics, and recurring software-as-a-service subscriptions.

Geographically, the South will maintain commercial revenue leadership, propelled by high female population numbers, nation-leading birth volumes, and maternal health equity initiatives across Texas, Florida, North Carolina, and Georgia. The West will maintain its position as the fastest-growing and technically advanced regional market, driven by California’s innovation ecosystem, early clinical technology adoption, and high consumer spending on direct-to-consumer digital health hardware. The Midwest will continue to provide a foundation of capital equipment procurement and clinical research across academic medical centers and health systems. The Northeast will remain the country’s most specialized, evidence-driven regional market, distinguished by elite academic teaching institutions and specialist referral hospitals that establish national clinical care standards.

For medical device manufacturers, institutional healthcare investors, digital health platforms, and hospital procurement executives, competitive advantage through 2032 will belong to enterprises that deliver integrated, interoperable clinical ecosystems. Hardware excellence alone is no longer sufficient to secure sustainable market leadership. Winning vendors will successfully combine high-reliability physical devices with intelligent edge artificial intelligence, seamless EHR interoperability, robust randomized controlled clinical trial validation, formal payer reimbursement pathways, and user-centric industrial designs tailored to female biological health metrics. Companies that execute this integrated clinical workflow model will capture durable lifetime value and define the standard of care across the expanding U.S. smart women’s health devices landscape through 2032.